...
首页> 外文期刊>Oncogene >CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer
【24h】

CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer

机译:CFTR通过靶向尿激酶纤溶酶原激活剂(uPA)的miR-193b抑制前列腺癌的肿瘤进展

获取原文
           

摘要

Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is expressed in the epithelial cells of a wide range of organs/tissues from which most cancers are derived. Although accumulating reports have indicated the association of cancer incidence with genetic variations in CFTR gene, the exact role of CFTR in cancer development and the possible underlying mechanism have not been elucidated. Here, we report that CFTR expression is significantly decreased in both prostate cancer cell lines and human prostate cancer tissue samples. Overexpression of CFTR in prostate cancer cell lines suppresses tumor progression (cell growth, adhesion and migration), whereas knockdown of CFTR leads to enhanced malignancies both in vitro and in vivo . In addition, we demonstrate that CFTR knockdown-enhanced cell proliferation, cell invasion and migration are significantly reversed by antibodies against either urokinase plasminogen activator (uPA) or uPA receptor (uPAR), which are known to be involved in various malignant traits of cancer development. More interestingly, overexpression of CFTR suppresses uPA by upregulating the recently described tumor suppressor microRNA-193b (miR-193b), and overexpression of pre-miR-193b significantly reverses CFTR knockdown-enhanced malignant phenotype and abrogates elevated uPA activity in prostate cancer cell line. Finally, we show that CFTR gene transfer results in significant tumor repression in prostate cancer xenografts in vivo . Taken together, the present study has demonstrated a previously undefined tumor-suppressing role of CFTR and its involvement in regulation of miR-193b in prostate cancer development.
机译:囊性纤维化(CF)跨膜电导调节剂(CFTR)在大多数癌症源自的广泛器官/组织的上皮细胞中表达。尽管越来越多的报道表明,癌症发病率与CFTR基因的遗传变异之间存在关联,但尚未阐明CFTR在癌症发展中的确切作用以及可能的潜在机制。在这里,我们报告CFTR表达在前列腺癌细胞系和人类前列腺癌组织样品中均显着降低。 CFTR在前列腺癌细胞系中的过表达抑制肿瘤进展(细胞生长,粘附和迁移),而敲除CFTR则导致体外和体内恶性肿瘤增强。此外,我们证明,针对尿激酶纤溶酶原激活物(uPA)或uPA受体(uPAR)的抗体可显着逆转CFTR敲低增强的细胞增殖,细胞侵袭和迁移,而尿激酶纤溶酶原激活物(uPA)或uPA受体(uPAR)已知参与癌症发展的各种恶性特征。更有趣的是,CFTR的过表达通过上调最近描述的肿瘤抑制物microRNA-193b(miR-193b)来抑制uPA,pre-miR-193b的过表达显着逆转CFTR敲低的恶性表型,并消除前列腺癌细胞系中uPA活性的升高。 。最后,我们显示CFTR基因转移导致体内前列腺癌异种移植物中显着的肿瘤抑制。综上所述,本研究已经证明了CFTR先前未定义的肿瘤抑制作用及其在前列腺癌发展中参与miR-193b的调控。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号